D.E. Shaw & Co
INBX

D.E. Shaw & Co’s Inhibrx, Inc. Common Stock INBX Stock Holding History

D.E. Shaw & Co’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,497
Closed -$922K – 4689
2023
Q2 		$922K Sell
35,497
-55,353
-61% -$1.29M ﹤0.01% 3145
2023
Q1 		$1.71M Sell
90,850
-10,390
-10% -$242K ﹤0.01% 2805
2022
Q4 		$2.49M Buy
101,240
+31,521
+45% +$927K ﹤0.01% 2751
2022
Q3 		$1.25M Sell
69,719
-51,293
-42% -$925K ﹤0.01% 3423
2022
Q2 		$1.37M Buy
121,012
+85,016
+236% +$1.25M ﹤0.01% 3402
2022
Q1 		$802K Buy
35,996
+22,187
+161% +$566K ﹤0.01% 4079
2021
Q4 		$603K Buy
+13,809
New +$552K ﹤0.01% 4295

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

D.E. Shaw & Co's INBX Position: Q3 2023 in Review

D.E. Shaw & Co sold out of Inhibrx, Inc. Common Stock (INBX) in Q3 2023, closing a stake of 35,497 shares — an estimated $922K sold.

D.E. Shaw & Co first reported a position in INBX in Q4 2021 and held it in 7 quarters. The position peaked at $2.49M in Q4 2022. 111 funds tracked by Wall St. Rank hold INBX as of Q3 2023.

  • D.E. Shaw & Co reported no remaining Inhibrx, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 35,497 Inhibrx, Inc. Common Stock shares in Q3 2023, an estimated $922K.
  • D.E. Shaw & Co first reported a position in Inhibrx, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • D.E. Shaw & Co's Inhibrx, Inc. Common Stock position peaked at $2.49M in Q4 2022.
  • 111 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q3 2023.

Based on D.E. Shaw & Co's 13F filing for Q3 2023, filed 14 Nov 2023.